Insulet Corporation (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Insulet Corporation (NASDAQ:PODD) have been given an average recommendation of “Moderate Buy” by the twenty-four ratings firms that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $374.0952.

A number of research analysts recently weighed in on PODD shares. Evercore initiated coverage on shares of Insulet in a research note on Tuesday, December 16th. They set an “outperform” rating and a $370.00 target price on the stock. Zacks Research downgraded Insulet from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Leerink Partners upped their price objective on Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Barclays lifted their target price on Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada upped their price target on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $242.74 on Tuesday. The company has a market capitalization of $17.08 billion, a P/E ratio of 70.36, a P/E/G ratio of 1.37 and a beta of 1.41. Insulet has a 1-year low of $230.05 and a 1-year high of $354.88. The firm’s 50 day simple moving average is $276.12 and its two-hundred day simple moving average is $306.11. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PODD. Larson Financial Group LLC increased its holdings in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. Elyxium Wealth LLC bought a new position in Insulet during the fourth quarter valued at approximately $28,000. True Wealth Design LLC grew its holdings in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares in the last quarter. Golden State Wealth Management LLC increased its stake in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares during the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA increased its stake in Insulet by 68.8% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 55 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.